p450 - publications

Predict more p450 - ligand interactions now!

1. Neuro Endocrinol Lett. 2012 Apr 17;33(2):236-244. [Epub ahead of print]

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated
with risperidone.

[No authors listed]

OBJECTIVE: The objective of this prospective, naturalistic study, conducted in
first-episode psychosis patients from a Central-European population, was to
assess the utility of Cytochrome P-450 2D6 (CYP2D6) genotype testing under normal
clinical setting. METHODS: A total of 35 patients diagnosed for the first time
with schizophrenia or acute schizophrenia-like psychotic disorder and treated
with risperidone were enrolled in the study. These patients underwent
sequentiation of the CYP2D6 gene and evaluations of symptoms and severity of
adverse effects using the PANSS and UKU scales, respectively. Doses of
antipsychotics and other co-medication were monitored as well. In statistical
analysis, Fisher's exact test was used to compare ratios and the Wilcoxon
rank-sum test was used in the comparison of continual variables. RESULTS: PM
patients showed a significantly lower reduction in psychotic symptoms and a
greater severity of psychotic symptoms following risperidone treatment and higher
doses of antipsychotics not metabolized by CYP2D6, which were used as
co-medication. CONCLUSIONS: Based on these results, patients with the PM genotype
experiencing first-episode schizophrenia don't appear to be optimal recipients of
risperidone treatment. However, as the main limitation of this study was the
relatively small sample-size, replication with a larger scale study is needed to
confirm these findings.

PMID: 22592207 [PubMed - as supplied by publisher]